DiaMedica Therapeutics Inc
DMAC
NASDAQ
Biotechnology
$6.68
USD
-0.07 (-1.04%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $360.76M
Volume 165.2K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-35.10M
TTM
-30.0%
YoY
Operating Cash Flow
$-31.00M
TTM
-37.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.5 | 2.2 | 2.6 | 2.5 | 2.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 8.1 | 8.0 | 9.0 | 9.2 | 10.5 |
Operating Income | -8.1 | -8.0 | -9.0 | -9.2 | -10.5 |
EBITDA | -8.1 | -8.0 | -9.0 | -9.2 | -10.5 |
Other Income / Expense | 0.4 | 0.3 | 0.4 | 0.5 | 0.4 |
Total Other Income / Expense | 0.4 | 0.3 | 0.4 | 0.5 | 0.4 |
Income Before Income Taxes | -7.7 | -7.7 | -8.6 | -8.7 | -10.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -7.7 | -7.7 | -8.6 | -8.7 | -10.0 |
Consolidated Net Income / Loss | -7.7 | -7.7 | -8.6 | -8.7 | -10.0 |
Net Income Attributable to Common Shareholders | -7.7 | -7.7 | -8.6 | -8.7 | -10.0 |
Basic EPS | -$0.18 | -$0.18 | -$0.17 | -$0.17 | -$0.19 |
Diluted EPS | -$0.18 | -$0.18 | -$0.17 | -$0.17 | -$0.19 |
Basic Shares Outstanding | 42.8M | 43.0M | 49.6M | 52.5M | 53.8M |
Diluted Shares Outstanding | 42.8M | 43.0M | 49.6M | 52.5M | 53.8M |